ACADIA Pharmaceuticals Inc. ((ACAD)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: ACADIA Pharmaceuticals Inc. is conducting a clinical study titled ‘A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer’s Disease Psychosis.’ The study aims to evaluate the efficacy and safety of ACP-204, a treatment for Alzheimer’s Disease Psychosis (ADP), through three independent substudies. This research is significant as it addresses a critical need for effective treatments in ADP.
Intervention/Treatment: The study tests ACP-204, a drug acting as a selective antagonist/inverse agonist of the serotonin receptor subtype 2A. It is administered in doses of 30 mg and 60 mg, with a placebo group for comparison, aiming to alleviate symptoms of ADP.
Study Design: This interventional study is randomized with a parallel assignment model. It employs quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose is treatment, focusing on the therapeutic potential of ACP-204.
Study Timeline: The study began on November 14, 2023, with primary completion expected in January 28. The latest update was submitted on October 27, 2025. These dates are crucial for tracking the study’s progress and upcoming results.
Market Implications: This update could positively influence ACADIA Pharmaceuticals’ stock performance by demonstrating progress in addressing ADP. The study’s success may enhance investor confidence and position ACADIA favorably against competitors in the Alzheimer’s treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.